Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +18.29%
#3 Glidr Glidr +11.78%
#4 SkyAI SkyAI +10.14%
#5 Bitway Bitway +9.91%
#6 OPENLOOT OPENLOOT +8.85%
#7 Pump.fun Pump.fun +7.99%
#8 Unit Pump Unit Pump +7.99%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.84%
#10 Monad Monad +6.79%
Coin of the day
PulseChain PulseChain
Настройки
Язык
Pусский
Валюта
USD
Тема
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Ранг среди акций #28042
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Цена акции
$0.55
Последняя синхронизация: 2025-02-11
Рыночная капитализация
$28.90M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Marinus Pharmaceuticals, Inc. (MRNS)

Категория

Healthcare
Выручка компании Marinus Pharmaceuticals, Inc. (MRNS)
Выручка на Sep 2024 TTM: $31.47M
Согласно последним финансовым отчетам Marinus Pharmaceuticals, Inc., текущая выручка компании (TTM) составляет $31.47M. В 2022 году компания получила выручку $25.48M больше, чем выручке в 2021 году, которая составила $15.35M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Marinus Pharmaceuticals, Inc. с 2012 по 2026
Выручка на конец каждого года
Год Выручка Изменить
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH